Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

What is this patent about?

’829 is related to the field of recombinant protein production in mammalian cell cultures, specifically focusing on the post-translational modification of glycoproteins. In the manufacturing of therapeutic monoclonal antibodies, the specific arrangement of sugar molecules, or glycosylation profile, is a critical quality attribute that influences the drug's efficacy, serum clearance, and immune system interaction. A common challenge in the industry is the unwanted accumulation of high mannose glycoforms, which can negatively impact the pharmacokinetic properties of the resulting medicine.

The underlying idea behind ’829 is that the bottleneck in the cellular machinery responsible for processing complex sugars can be bypassed by genetically augmenting the N-glycosylation pathway. Rather than relying on traditional process-based interventions like adjusting pH, temperature, or media chemistry—which often inadvertently reduce overall yield—the invention targets the internal enzymatic capacity of the host cell. By forcing the overexpression of specific enzymes and transporters, the cell is better equipped to convert immature high-mannose structures into mature complex glycans, even at high production titers.

The claims of ’829 focus on a method for regulating high mannose glycoform content by transfecting a mammalian host cell to overexpress at least one of three specific proteins: N-acetyl-glucosaminyltransferase-1 (Mgat1), N-acetyl-glucosaminyltransferase-2 (Mgat2), or the UDP-Galactose transporter (Slc35a2). The claims specifically cover the use of these genetic modifications to ensure that the final recombinant protein maintains a high mannose content of 10% or less, providing a molecular solution to a macroscopic manufacturing problem.

In practice, the invention is implemented by introducing expression vectors into host cells, such as CHO cells, either before or after the cell has been engineered to produce a specific therapeutic protein. The data suggests that overexpressing a combination of these proteins, particularly Mgat1 and Mgat2, creates a synergistic effect that significantly drives down the presence of species like Mannose 5 (Man5). This metabolic engineering ensures that as the protein moves through the Golgi apparatus, the increased enzymatic density facilitates a more complete conversion to complex, fucosylated glycoforms.

This approach differs from prior art by providing a genetic baseline for glycan control that is independent of the specific cell culture media or bioreactor conditions. While previous methods often required a trial-and-error approach to media supplementation that could compromise cell viability or antibody productivity, this invention stabilizes the quality attribute at the genomic level. By optimizing the intracellular flux of the glycosylation pathway, manufacturers can achieve high-titer production without the typical trade-off in product quality or the risk of accelerated serum clearance.